A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or Metastasectomy
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 04 Oct 2024 Planned End Date changed from 1 Sep 2025 to 30 Sep 2026.
- 04 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 30 Sep 2025.
- 04 Oct 2024 Status changed from active, no longer recruiting to recruiting.